190 related articles for article (PubMed ID: 24102404)
1. Global clinical response in Cushing's syndrome patients treated with mifepristone.
Katznelson L; Loriaux DL; Feldman D; Braunstein GD; Schteingart DE; Gross C
Clin Endocrinol (Oxf); 2014 Apr; 80(4):562-9. PubMed ID: 24102404
[TBL] [Abstract][Full Text] [Related]
2. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
[TBL] [Abstract][Full Text] [Related]
3. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
Fein HG; Vaughan TB; Kushner H; Cram D; Nguyen D
BMC Endocr Disord; 2015 Oct; 15():63. PubMed ID: 26507877
[TBL] [Abstract][Full Text] [Related]
4. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
Castinetti F; Brue T; Conte-Devolx B
Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone for management of Cushing's syndrome.
Morgan FH; Laufgraben MJ
Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
[TBL] [Abstract][Full Text] [Related]
6. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
[TBL] [Abstract][Full Text] [Related]
7. Mifepristone: treatment of Cushing's syndrome.
Sartor O; Cutler GB
Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
[TBL] [Abstract][Full Text] [Related]
8. Merits and pitfalls of mifepristone in Cushing's syndrome.
Castinetti F; Fassnacht M; Johanssen S; Terzolo M; Bouchard P; Chanson P; Do Cao C; Morange I; Picó A; Ouzounian S; Young J; Hahner S; Brue T; Allolio B; Conte-Devolx B
Eur J Endocrinol; 2009 Jun; 160(6):1003-10. PubMed ID: 19289534
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
Castinetti F; Conte-Devolx B; Brue T
Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
[TBL] [Abstract][Full Text] [Related]
10. The use of mifepristone in the treatment of Cushing's syndrome.
Carroll T; Findling JW
Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.
Banerjee RR; Marina N; Katznelson L; Feldman BJ
Pediatrics; 2015 Nov; 136(5):e1377-81. PubMed ID: 26459648
[TBL] [Abstract][Full Text] [Related]
12. Medical management of Cushing's syndrome.
Vance ML
Endocr Pract; 2013; 19(2):193. PubMed ID: 23598532
[No Abstract] [Full Text] [Related]
13. ASSOCIATION BETWEEN MIFEPRISTONE DOSE, EFFICACY, AND TOLERABILITY IN PATIENTS WITH CUSHING SYNDROME.
Yuen KC; Williams G; Kushner H; Nguyen D
Endocr Pract; 2015 Oct; 21(10):1087-92. PubMed ID: 26121447
[TBL] [Abstract][Full Text] [Related]
14. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Pivonello R; Bancos I; Feelders RA; Kargi AY; Kerr JM; Gordon MB; Mariash CN; Terzolo M; Ellison N; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():662865. PubMed ID: 34335465
[TBL] [Abstract][Full Text] [Related]
15. Drugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide.
Schteingart DE
Expert Opin Emerg Drugs; 2012 Sep; 17(3):279-83. PubMed ID: 22533823
[No Abstract] [Full Text] [Related]
16. FKBP5 mRNA Expression Is a Biomarker for GR Antagonism.
Bali U; Phillips T; Hunt H; Unitt J
J Clin Endocrinol Metab; 2016 Nov; 101(11):4305-4312. PubMed ID: 27459525
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.
de Bruin C; Hofland LJ; Nieman LK; van Koetsveld PM; Waaijers AM; Sprij-Mooij DM; van Essen M; Lamberts SW; de Herder WW; Feelders RA
J Clin Endocrinol Metab; 2012 Feb; 97(2):455-62. PubMed ID: 22090282
[TBL] [Abstract][Full Text] [Related]
18. Mifepristone (RU 486) in Cushing's syndrome.
Johanssen S; Allolio B
Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid receptor blockers.
Molitch ME
Pituitary; 2022 Oct; 25(5):733-736. PubMed ID: 35507245
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties.
Sun Y; Fang M; Davies H; Hu Z
Gynecol Endocrinol; 2014 Mar; 30(3):169-73. PubMed ID: 24205903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
